Page 7 - Sohini Das

MedTherapy bets on low-cost CAR-T manufacturing with Noida CDMO push

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

Crisil stress test reveals sectors facing risk, and those less affected

Crisil states 22 of the 34 sectors stress-tested could see operating profitability decline by over 10 per cent as companies may not be able to fully pass on higher costs to consumers immediately

Mounting costs turn the heat on India Inc amid West Asia conflict

Firms diversify sourcing, redraw playbook, increase prices to tide over crisis

Indian drugmakers deepen US bets despite decline in pharma exports

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

West Asia conflict: EV cost edge sharpens amid rising fuel prices

Petrol, diesel have seen cumulative hike of ₹5 per litre in May

CCI says hospitals not automatic monopolies over admitted patients

Max hospitals, Indraprastha among chains involved in series of 12 orders

NephroPlus sharpens global dialysis push as overseas business grows

NephroPlus said overseas markets now contribute nearly 42 per cent of revenue as the dialysis provider expands globally through acquisitions, PPP projects and clinic additions

India could emerge as $7 bn MedTech contract manufacturing hub by 2035

India's overall MedTech opportunity could expand more than fourfold to $83-89 billion by 2035, driven by rising domestic demand, exports and contract manufacturing

Top carmakers remain bullish on FY27 domestic demand amid global risks

Auto companies have not cut back on capex and are planning new launches, even as they remain cautious about margins amid input costs and supply-chain risks

Tata Motors PV sees profitability in electric vehicles, reduced costs

The company said falling battery costs, localisation and tighter emission norms for petrol and diesel vehicles are steadily improving the long-term economics of electric vehicles

JLR may retain ICE models longer in US amid high tariff, EV market shifts

Jaguar Land Rover said changing market dynamics and tariff pressures may require it to keep internal combustion engine vehicles in its US portfolio for longer

Automakers ramp up production with dispatches, exports powering FY27

PV production trails dispatch growth, signaling inventory normalisation; 2W and 3W exports rebound

Tata Motors cautions on fuel cost as the biggest risk to the CV recovery

Tata Motors said rising diesel prices linked to the Middle East crisis could threaten India's commercial vehicle recovery by sharply increasing operating costs for fleet operators

Tata Motors PV profit slumps 32% to ₹5,783 crore on JLR headwinds

India passenger vehicle business records strong growth, while Jaguar Land Rover profitability remains under pressure from tariffs and weak China demand

Zydus to acquire Assertio in ₹1,570 crore deal to expand US business

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Tata Motors Q4 PAT rises 34% to ₹1,793 cr on strong operational performance

Commercial vehicle maker reports higher volumes, stronger margins and record annual revenue despite headwinds from commodity prices and West Asia tensions

Tata-backed Impetis licenses JAK inhibitor assets to Vyome Holdings

Deal gives Vyome entry into the fast-growing market for next-generation autoimmune and inflammatory disease drugs

Passenger vehicle sales seen hitting record 5.9 mn units in FY27: Crisil

Crisil Ratings expects India's passenger vehicle industry to post record sales this fiscal, supported by GST-led demand recovery and continued preference for utility vehicles

100 years on, Bajaj Group begins to build anew for India's future growth

Bajaj Group's centenary is less a celebration than a pivot into healthcare, electric mobility and the AI age

India joins weight-loss drug race, but affordability remains a concern

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?